Insulet stock falls after Q2 2026 guidance miss despite strong revenue growth

Published on 09/15/2026 at 16:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Insulet stock trades around USD 132.50 as of September 14, 2026, after a sharp drop following Q2 2026 results and softer revenue guidance. The company reported Q2 2026 revenue of USD 801.7 million, up 23.5 percent year on year, but next-quarter guidance missed analysts’ expectations.

Flatlay Insulet – Aktienzertifikat, ISIN-Karte US45784P1012, Pod-Gerät und Stethoskop auf Marmor — Insulet Aktien-Flatlay auf weißem Marmor mit Börsenzertifikat, ISIN-Karte US45784P1012, Insulin-Pod und Stethoskop, Illustration mit AI erstellt.

Insulet Corporation stock (ISIN US45784P1012) is trading around USD 132.50 as of September 14, 2026, after a notable pullback triggered by its latest quarterly results and softer revenue guidance for the coming quarter, according to Yahoo Finance.

Q2 2026 revenue grows more than 20 percent

As Yahoo Finance reported on September 14, 2026, Insulet generated revenue of USD 801.7 million in the second quarter of 2026, an increase of 23.5 percent compared with the same quarter a year earlier.

The same analysis notes that Insulet’s Q2 2026 revenue came in about 1.9 percent above the consensus forecast from analysts, indicating a clear beat versus expectations on the top line, according to Yahoo Finance.

Guidance miss weighs on Insulet stock

Despite the strong revenue growth and an earnings-per-share beat in Q2 2026, Insulet’s guidance for revenue in the following quarter was described as missing analysts’ expectations significantly, which has become the dominant risk factor for the stock in the near term, according to Yahoo Finance.

Following the Q2 2026 release and the cautious revenue outlook, Insulet shares are down 20.6 percent from their level before the results and currently trade at about USD 132.50 per share, according to the same Yahoo Finance analysis.

Valuation and investor perspective

In a separate overview of S&P 500 healthcare names, Insulet’s valuation is highlighted with the stock trading at roughly 19.5 times forward earnings at a share price of USD 132.50 and a market capitalization of about USD 9.15 billion as of mid-September 2026, according to Yahoo Finance.

For investors, the quantified combination of a 23.5 percent year-on-year revenue increase in Q2 2026, a 1.9 percent top-line beat versus consensus, and a 20.6 percent share price decline since the results underscores how heavily the market now weighs future growth expectations and the trajectory of Insulet’s guidance.

Insulet stock price level as of the last trading day

As of the last completed trading day before September 15, 2026, Insulet stock is quoted around USD 132.50 on Nasdaq, with the shares having lost 20.6 percent since their level prior to the Q2 2026 announcement, based on data summarized by Yahoo Finance.